SEARCH

SEARCH BY CITATION

References

  • 1
    Di Bisceglie AM, Goodman ZD, Ishak KG, et al. Long term clinical and histopathological follow-up of chronic post-transfusion hepatitis. Hepatology 1991; 14: 969 74.
  • 2
    Tsukuma H, Hiyama T, Tanaka S, et al. Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N Engl J Med 1993; 328: 1797 801.
  • 3
    Hoofnagle JH & Di Bisceglie AM. The treatment of chronic viral hepatitis. N Engl J Med 1997; 336: 347 56.
  • 4
    Fujisawa K & Tandon BN. Therapeutic approach to the chronic active liver disease: Summary of a satellite symposium. In: Nishioka K, Suzuki H, Mishiro S, Oda T, eds. Viral Hepatitis and Liver Disease. Tokyo: Springer, 1994: 662 5.
  • 5
    Spinks EA & Fenwick GR. The determination of glycyrrhizin in selected UK liquorice products. Food Addit Contam 1990; 7: 769 78.
  • 6
    Revers FE. Heeft Succus Liquiritae een genezende werking op de Maagzweer. Ned Tijdschr Geneeskd 1946; 90: 135 7.
  • 7
    Suzuki H, Ohta Y, Takino T, Fujisawa K, Hirayama C. The therapeutic effects of Stronger Neo Minophagen C for chronic hepatitis. Igaku no Ayumi 1977; 102: 562 8.
  • 8
    Hino K, Miyakawa H, Kondo T, et al. Effects of glycyrrhizin therapy on liver histology in chronic aggressive hepatitis. In: Shikata T, Porcell RH, Uchida T, eds. Viral hepatitis C, D and E. Amsterdam: Excerpta Medica, 1987: 295 303.
  • 9
    Hattori M. Metabolism of glycyrrhizin by human intestinal flora II. Isolation and characterization of human intestinal bacteria capable of metabolizing glycyrrhizin and related compounds. Chem Pharm Bull 1985; 33: 210 17.
  • 10
    Akao T, Akao T, Hattori M, et al. Hydrolysis of glycyrrhizin to 18 β-glycyrrhetyl monoglucuronide by lysosomal β-D-glucuronidase of animal livers. Biochem Pharmacol 1991; 41: 1025 9.
  • 11
    Yamamura Y, Kawakami J, Snata T, et al. Pharmacokinetic profile of glycyrrhizin in healthy volunteers by a new high-performance liquid chromatographic methodJ Pharm Sci 1992; 81: 1042 6.
  • 12
    Tanaka N, Yamamura Y, Santa T, et al. Pharmacokinetic profiles of glycyrrhizin in patients with chronic hepatitis. Biopharm Drug Dispos 1993; 14: 609 14.
  • 13
    Yamamura Y, Tanaka N, Santa T, et al. The relationship between pharmacokinetic behaviour of glycyrrhizin and hepatic function in patients with acute hepatitis and liver cirrhosis. Biopharm Drug Dispos 1995; 16: 13 21.
  • 14
    Conn JW, Rovner DR, Cohen EL. Licorice-induced pseudoaldosteronism. J Am Med Assoc 1968; 205: 492 6.
  • 15
    Stewart PM, Wallace AM, Valentino R, et al. Mineralocorticoid activity of liquorice: 11-beta-hydroxysteroid dehydrogenase deficiency comes of age. Lancet 1987; ii: 821 3.
  • 16
    Walker BR & Best R. Clinical investigation of 11 β-hydroxysteroid dehydrogenase. Endocr Res 1995; 21: 379 87.
  • 17
    Stewart PM, Wallace AM, Atherden SM, Shearing CH, Edwards CRW. Mineralocorticoid activity of carbenoloxone: contrasting effects of carbenoxolone and liquorice on 11 β-hydroxysteroid dehydrogenase activity in man. Clin Sci 1990; 78: 49 54.
  • 18
    Kageyama Y, Suzuki H, Saruta T. Glycyrrhizin induces mineralocorticoid activity through alterations in cortisol metabolism in the human kindney. J Endocrinol 1992; 135: 147 52.
  • 19
    Farese RV, Biglieri EG, Shackleton CHL, Irony I, Gomez-Fontes R. Licorice-induced hypermineralocorticoidism. N Engl J Med 1991; 325: 1223 7.
  • 20
    Bernardi M, D’intino PE, Trevisani F, et al. Effects of prolonged ingestion of graded doses of licorice by healthy volunteers. Life Sci 1994; 55: 863 72.
  • 21
    Kageyama Y, Suzuki H, Saruta T. Renin-dependency of glycyrrhizin-induced pseudoaldosteronism. Endocrinol Jpn 1991; 38: 103 8.
  • 22
    Bocker D & Breithardt G. Arrhytmieausloung durch Lakritzabusus. Z Kardiol 1991; 80: 389 91.
  • 23
    Bannister B, Ginsburg R, Shneerson J. Cardiac arrest due to liquorice-induced hypokalaemia. Br Med J 1977; ii: 738 9.
  • 24
    Heidemann HT & Kreuzfelder E, Hypokalemic rhabdomyolysis with myoglobinuria due to licorice ingestion and diuretic treatment. Klin Wochenschr 1983; 61: 303 5.
  • 25
    Gross EG, Dexter JD, Roth RG. Hypokalemic myopathy with myoglobinuria associated with licorice ingestion. N Engl J Med 1966; 274: 602 6.
  • 26
    Nielsen I & Pederson RS. Life-threatening hypokalaemia caused by liquorice ingestion. Lancet 1984; i: 1305.
  • 27
    Pompei R, Flore O, Marccialis MA, Pani A, Loddo B. Glycyrrhizic acid inhibits virus growth and inactivates virus particles. Nature 1979; 281: 689 90.
  • 28
    Crance JM, Biziagos E, Passagot J, Van Cuyck-Gandré H, Deloince R. Inhibition of hepatitis A virus replication in vitro by antiviral compounds. J Med Virol 1990; 31: 155 60.
  • 29
    Crance JM, Lévêque F, Biziagos E, et al. Studies on the mechanism of action of glycyrrhizin against hepatitis A virus replication in vitro. Antiviral Res 1994; 23: 63 76.
  • 30
    Shiki Y, Shirai K, Saito Y, et al. Effect of glycyrrhizin on lysis of hepatocyte membranes induced by anti-liver cell membrane antibody. J Gastroenterol Hepatol 1992; 7: 12 16.
  • 31
    Nakamura T, Fujii T, Ichihara A. Enzyme leakage due to change of membrane permeability of primary cultured rat hepatocytes treated with various hepatotoxins and its prevention by glycyrrhizin. Cell Biol Toxicol 1985; 1: 285 95.
  • 32
    Nose M, Ito M, Kamimura K, Shimizu M, Ogihara Y. A comparison of the antihepatotoxic activity between glycyrrhizin and glycyrrhetinic acid. Planta Med 1994; 60: 136 9.
  • 33
    Nagai T, Egashira T, Yamanaka Y, Kohno M. The protective effect of glycyrrhizin against injury of the liver caused by ischemia-reperfusion. Arch Environ Contam Toxicol 1991; 20: 432 6.
  • 34
    Nagai T, Egashira T, Kudo Y, Yamanaka Y, Shimada T. Attenuation of disfunction in the ischemia-reperfused liver by glycyrrhizin. Jpn J Pharmacol 1992; 58: 209 18.
  • 35
    Takahara T, Watanabe A, Shiraki K. Effects of glycyrrhizin on hepatitis B surface antigen: a biochemical and morphological study. J Hepatol 1994; 21: 601 9.
  • 36
    Abe N, Ebina T, Ishida N. Interferon induction by glycyrrhizin and glycyrrhetinic acid in mice. Microbiol Immunol 1982; 26: 535 9.
  • 37
    Kimura M, Watanabe H, Abo T. Selective activation of extrathymic T cells in the liver by glycyrrhizin. Biotherapy 1992; 5: 167 76.
  • 38
    Suzuki H, Ohta Y, Takino T, Fujisawa K, Hirayama C. Effects of glycyrrhizin on biochemical tests in patients with chronic hepatitis. Asian Med J 1983; 26: 423 38.
  • 39
    Yasuda K, Hino K, Fujioka S, et al. Effects of high dose therapy with Stronger Neo Minophagen C (SNMC) on hepatic histography in non-A, non-B chronic active hepatitis. In: Shikata T, Purcell RH, Uchida T, eds. Viral Hepatitis C, D and E. Amsterdam: Excerpta Medica, 1991: 205 9.
  • 40
    Xianshi S, Huiming C, Lizhuang W, Chuanfa J, Jianhui L. Clinical and laboratory observation on the effect of glycyrrhizin in acute and chronic viral hepatitis. J Tradit Chin Med 1984; 4: 127 32.
  • 41
    Wildhirt E. Experience in Germany with glycyrrhizinic acid for the treatment of chronic viral hepatitis. In: Nishioka K, Suzuki H, Mishiro S, Oda T, eds. Viral Hepatitis and Liver Disease. Tokyo: Springer-Verlag, 1994: 658–61.
  • 42
    Arase Y, Ikeda K, Murashima N, et al. The long term efficacy of glycyrrhizin in chronic hepatitis C patients. Cancer 1997; 79: 1494 500.
  • 43
    Hoofnagle JH, Lau D, Conjeevaram H, Kleiner D, Di Bisceglie AM. Prolonged therapy of chronic hepatitis C with ribavirin. J Viral Hepatitis 1996; 3: 247 52.